The Role of Secondary Metabolites on Gynecologic Cancer Therapy: Some Pathways and Mechanisms

Abstract

ÖZJinekolojik kanserler insanlarda ve hayvanlarda en yaygın görülen kanserler arasındadır. Tedavi başarısı tanıdaki evre, tümör tipi, orijini ve metastazı içeren birçok faktöre bağlıdır. Günümüzde bu kanserlerin tedavisinde, cerrahi müdahale, kemoterapi ve radyoterapi uygulanmaktadır. Ancak, birçok anti-karsinojenik ilaç ciddi yan etkilere neden olabilir ve ayrıca tedaviye beklenen yanıt alınamayabilir. Son yıllarda yapılan çalışmalarda kanser ve inflamasyon arasındaki ilişkinin önemi vurgulanmıştır. Ve bununla birlikte, inflamatuvar yolaklara karşı yararlı biyoaktif etkiler gösteren birçok fitokimyasalın jinekolojik kanser tedavisi için antikarsinojenik potansiyele sahip olduğu kanıtlanmıştır. Bu derlemede, jinekolojik kanserlerdeki inflamatuvar yolaklar ve bu yolaklarda etkili sekonder metabolitlerin tedavideki rolü özetlenmektedir. Anahtar kelimeler: Jinekolojik kanserler, yolak, sekonder metabolitler, bitkisel bileşenler, inflamasyon Gynecologic cancers are among the most common cancers in humans and animals. Treatment success depends on several factors including stage at diagnosis, tumor type, origin and metastasis. Currently, surgery, chemotherapy, and radiotherapy are preferred in the treatment of these cancers. However, many anticarcinogenic drugs can cause severe adverse effects and also the expected response to treatment may not be obtained. In recent studies, the importance of the relationship between cancer and inflammation has been emphasized. Therefore, several phytochemicals that exhibit beneficial bioactive effects towards inflammatory pathways were proven to have anticarcinogenic potential for gynecologic cancer therapy. This review summarizes the role of inflammatory pathways in gynecologic cancers and effective secondary metabolites for cancer therapy.

α-Mangostin Nanoparticles Cytotoxicity and Cell Death Modalities in Breast Cancer Cell Lines

“…Over 200 novel chemical compounds have been licensed for use in the battle against cancer in the last 50 years, with about 50% being molecules of unaltered natural products [ 21 ]. Small organic molecules of secondary metabolites have played an essential role in inhibiting proliferation-induced apoptosis or other modifiable mechanisms [ 22 , 23 , 24 ]. Natural products and their derivatives have been recognized for many years by the pharmaceutical industry [ 25 , 26 ].…”